There may be a “silver bullet” for Ebola, a family of hemorrhagic viruses, one of which has killed more than 11,000 people in West Africa in the past two years.

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2015.

James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, and Anthony Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), recently participated in a U.S. Senate National Institutes of Health (NIH) caucus briefing held in Washington, D.C., by Senate NIH caucus co-chairs Sens. Lindsey Graham (R-SC) and Dick Durbin (D-IL).

Two survivors of a 2014 Ebola outbreak in Nigeria visited Vanderbilt University Medical Center last week to share their experiences and participate in a study aimed at finding ways to treat the often-fatal infection.

Three Nigerian physicians who survived Ebola virus disease in July 2014 after coming in direct contact with an Ebola-infected patient will speak at Vanderbilt University Medical Center next Wednesday, Sept. 16.

Vanderbilt University researchers next month will launch a major initiative to acquire “dense genotypes” from 100,000 individuals whose medical histories are known.

Researchers at Vanderbilt University and the National University of Singapore have determined the structure of a human monoclonal antibody which, in an animal model, strongly neutralizes a type of the potentially lethal dengue virus.